National Bank of Canada’s Ultragenyx Pharmaceutical RARE Stock Holding History

National Bank of Canada’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-104	Closed	-$3.13K	–	3089
2025 Q3	$3.13K	Sell	104 -12	-10%	-$360	﹤0.01%	2534
2025 Q2	$4.22K	Buy	+116	New	+$4.18K	﹤0.01%	2520
2023 Q3	–	Sell	-4,063	Closed	-$190K	–	2867
2023 Q2	$190K	Sell	4,063 -1,150	-22%	-$53.3K	﹤0.01%	1477
2023 Q1	$211K	Buy	+5,213	New	+$224K	﹤0.01%	1397

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

National Bank of Canada's RARE Position: Q4 2025 in Review

National Bank of Canada sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 104 shares — an estimated $3.13K sold.

National Bank of Canada first reported a position in RARE in Q1 2023 and held it in 4 quarters. The position peaked at $211K in Q1 2023. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

National Bank of Canada reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
National Bank of Canada sold 104 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $3.13K.
National Bank of Canada first reported a position in Ultragenyx Pharmaceutical in Q1 2023 and held it in 4 quarters.
National Bank of Canada's Ultragenyx Pharmaceutical position peaked at $211K in Q1 2023.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on National Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.